medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2005, Number 3

<< Back Next >>

Rev Mex Urol 2005; 65 (3)

15Body mass index as prognosis factor in prostate cancer

Rodríguez CF, Castillejos MR, Figueroa GV, López CE, Feria BG

Language: Spanish
References: 15
Page: 166-170
PDF size: 53.50 Kb.


ABSTRACT

Introduction. Several studies have shown association between obesity and malignant diseases. About 35% of all cancers may be caused by dietary and nutritional factors. The association with prostate cancer (PC) is controversial and data about survival in patients undergoing radical prostatectomy (RP) are inconsistent. Objetive. We analyzed pathologic features, risk group and survival of patients with PC undergoing RP and the relationship with obesity. Results. Patients with body mass index (BMI) › 30 kg/m2 had a higher Gleason score (≥ 7) (p ‹ 0.027). Obesity was not associated with pathological stage (p › 0.05). There was a trend toward a higher likelihood of biochemical failure in obese patients (p = 0.181). Conclusions. At our Institute, patients with PC and BMI › 30 kg/m2 undergoing RP have a higher likelihood of harbouring high grade tumors after RP.


REFERENCES

  1. Mydlo JH, et al. The role of obesity and diet in urolgical carcinogenesis. BJU Int 1999; 84: 225-35.

  2. Amling CL, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439-45.

  3. Calle EE, et al. Overweight, obesity and mortality form cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.

  4. Freedland SJ, et al. Impact of obesity on biochemicalcontrol after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital Database Study Group. J Clin Oncol 2004; 22: 446-53.

  5. Sobón LH, Witteking C. Clasificación de los tumours malignos TNM. Internacional Union Against Cancer 1997.

  6. D’Amico AV, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.

  7. Rodríguez-Covarrubias F, et al. Recurrencia bioquímica según el grupo de riesgo en pacientes con Adenocarcinoma de próstata. Revista Mexicana de Urología 2004; 64: 6-12.

  8. 8. World Health Organization. Obesity: Preventing and managing the global epidemic – report of a WHO consultation on obesity. Geneva Switzarland, World Health Organization, 1997.

  9. Rivera-Dommarco J, Barquera S. Public Health Nutrition 2002; 5 (1A): 113-22.

  10. 10.Amling CL, et al. Relationship between obesity and race in pedicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001; 58: 723-8.

  11. 11.Freedland SJ, et al. Obesity and biochemical ourcome following radical prostatectomy for organ confined disease with negative surgical margins. Journal of Urology 2004; 172: 520-4.

  12. 12.Chang SS, et al. Predicting blood loss and transfusion requirements during radical prostatectomy: The significant negative impact of increasing body mass index. Journal of Urology 2004; 171: 1861-5.

  13. 13.Presti JC, et al. Lower body mass index is associated with higher prostate cancer detection rate and less favourable pathological features in a biopsy population. Journal of Urology 2004; 171: 2199-202.

  14. 14.Severson RK, et al. Body mass and prostate cancer: A prospective study. BMJ 1988; 297: 713-5.

  15. 15.Hubbard SJ, et al. Association of prostate cancer risk with insulin, glucose and anthropometry in the baltimore longitudinal study of aging. Urology 2004; 63: 253-8.




2020     |     www.medigraphic.com